Solutions
Online Inquiry

Genetically Modified Neural Stem Cell Lines

Genetically modified neural stem cell (NSC) lines serve as a pivotal model for investigating the pathophysiology of various brain tumors, including glioblastomas and medulloblastomas. Alfa Cytology offers comprehensive services for the development of genetically modified NSC lines specifically designed for brain tumors.

Introduction to Genetically Modified NSC Lines Model

Neural stem cells (NSCs) are cells that are capable of self-renewal and have the potential to differentiate into neurons, astrocytes, oligodendrocytes, and many other differentiation potentials. During development, NSCs are present in the neural tube and then gradually enter the subventricular zone, striatum, and hippocampus. Throughout the life cycle, new neurons are constantly produced. When the brain is damaged, some dormant NSCs will be activated.

Neurotransmitter probe neural stem cell lines

We provide genetically modified neural stem cell line development services and related products

Alfa Cytology offers genetically modified neural stem cell lines, which are genetically engineered to genetically modify neural stem cells to stably express specific exogenous genes, such as fluorescent proteins, neurotransmitter probes, calcium probes, and light-sensitive proteins. This enables real-time observation and precise manipulation of the cells, which can be applied to a variety of brain science research fields such as electrophysiology, optogenetics, and neural circuit tracing. Meanwhile, we can provide a neural stem cell-directed differentiation medium, which can differentiate neural stem cells into neural cell types of interest, providing customers with more convenient experimental conditions and improving the reproducibility of experiments.

Transmonosynaptic retrograde and biological markers neural stem cell lines

We use RV-En-vA-∆G-dsRed to bind to G protein-expressing helper viruses to achieve neuronal labeling across single synapses. Red fluorescent protein-labeled neurons were seen in brain regions.

Neurotransmitter probe neural stem cell lines

We use probes that can accurately detect neurotransmitter dynamics in real-time with high sensitivity, specificity, and resolution, and can be used to resolve complex functions of the nervous system at high temporal and spatial scales.

Calcium probe neural stem cell lines

We convert changes in calcium concentration into fluorescent signals using indicators that can sense Ca2+ concentration and provide you with a wide range of Ca2+ probe-based neural stem cell development and related products as a biotherapeutic approach to help you in your pioneering exploration in the field of brain tumors.

Voltage probe neural stem cell lines

We seek to develop voltage probe-like neural stem cell lines by combining nanoparticles or fluorescent molecular probes that are sensitive to changes in cell membrane potential and have high signal-to-noise ratios, thereby enabling in vivo detection of electrical activity in large clusters of neurons with high spatiotemporal resolution.

Optogenetic neural stem cell lines

We integrate optogenetic technology with electrophysiological and molecular biology techniques to provide you with optogenetic-based neural stem cell development services for the direct demonstration of behavioral outcomes exhibited by neuronal activation.

Chemical genetic neural stem cell lines

We modify the GPCR on the nerve cell membrane to obtain DREADDs, which are unable to bind the original neurotransmitter ligand, and control the cellular activity by adding or removing the specified drugs, thus allowing you to observe the different excitability changes in the nerve cells triggered by different drugs.

Alfa Cytology's technical services and products on genetically modified neural stem cells are still being iteratively updated. For more information, please feel free to contact us to customize your needs.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.